in the intraocular target site. Treatment of vitreoretinal diseases often include repeated intravitreous injections that are associated with adverse effects. Local administration of biodegradable microspheres offers an excellent alternative to multiple administrations, as they are able to deliver the therapeutic molecule in a controlled fashion. Furthermore, injection of microparticles is performed without the need for surgical procedures. As most of the retinal diseases are multifactorial, microspheres result especially promising because they can be loaded with more than one active substance and complemented with the inclusion of additives with pharmacological properties. Personalized therapy can be easily achieved by changing the amount of administered microspheres. Contrary to non-biodegradable devices, biodegradable PLA and PLGA microspheres disappear from the site of administration after delivering the drug. Furthermore, microspheres prepared from these mentioned biomaterials are well tolerated after periocular and intravitreal injections in animals and humans. After injection, PLA and PLGA microspheres suffer aggregation behaving like an implant. Biodegradable microspheres are potential tools in regenerative medicine for retinal repair. According to the reported results, presumably a variety of microparticulate formulations for different ophthalmic therapeutic uses will be available in the clinical practice in the near future.
Introduction
Pathologies affecting the posterior segment of the eye are one of the major causes of blindness in developed countries. These diseases include uveitis, diabetic retinopathy, macular edema, endophthalmitis, proliferative retinopathy, age related macular degeneration and glaucoma, among others. Generally, back of the eye diseases are chronic and degenerative.and some of them are related to elderly. Sucessful treatments of vitreoretinal diseases require effective concentrations of the active substance mantained during long periods in the target site. Statics barriers (different corneal layers, sclera, retina, blood aqueous and blood retinal barriers), dynamic barriers (tear dilution, conjunctival and choroidal blood flow, and lymphatic clearance) as well as efflux pumps, effectively limit the drug access to the posterior segment (Gaudana et al., 2010) . Four routes of administration can be theoretically employed to deliver active substances to treat retinal diseases: topical, systemic, intraocular and periocular (Herrero-Vanrell et al., 2001 ). The poor bioavailability of topically administered drugs limits their access to intraocular tissues. Systemic administration requires high doses to achieve adequate therapeutic levels of the drug in the eye with the risk of systemic adverse effects.
Intraocular local drug administration includes injections into the anterior chamber of the eye (intracameral), in the vitreous (intravitreal) or into the periocular tissues (subconjunctival, sub-Tenon and retrobulbar). Due to the difficulty in the maintenance of therapeutic concentrations in the target site, repeated intraocular injections are required for a successful therapy causing much inconvenience to patients. Although the periocular route is getting more attention, intravitreal injections are still the most employed even being associated to non-desired effect. For example, if high doses of the therapeutic agent are administered the concentration in the retina can be toxic. Besides, successive intravitreal injections are related to adverse effects such as cataracts, retinal detachment, and haemorraghes, among others. Moreover, the risk of the non-desired effects increases with the number of injections (Herrero-Vanrell et al., 2000) .
Innovative treatments as intraocular drug delivery systems have been developed to provide sustained drug concentrations of the active substance in the target site. They are constituted by a combination of drugs and biomaterials. Depending on the properties of the biomaterial (erodible or biodegradable and non-erodible or non-biodegradable), the devices can disappear from the site of administration or remain there during the lifetime of patients.
Depending on their size, devices are classified as implants (>1 mm), microparticles
(1-1000 μm) and nanoparticles (1-1000 nm). Considering their physical structure they are divided into reservoir and matrix systems (Herrero-Vanrell and Cardillo 2010b ).
Implants and microparticles are able to release the active substance during longer periods of time compared to nanoparticles (figure 1). Depending on their size, implantation procedure requires a surgical incision or a small perforation. Several nonbiodegradable implants and one erodible device have been approved for clinical use.
Non-biodegradable implants remain inside the eye or need a second surgery procedure to be removed. The non-biodegradable devices approved for clinical use are reservoir systems constituted by a nucleous of the drug surrounded by a layer of a mixture of polymers. They are loaded with antivirals (ganciclovir Vitrasert®) or anti-inflammatory drugs (fluocinolone acetonide Retisert™ and Medidur™). There is one biodegradable implant (0.45 x 6 mm) made of PLGA (Ozurdex). The matrix device is loaded with dexamethasone (700 μg) and is approved for the treatment of retinal vein occlusion, diabetic macular edema, uveitis and post-cataract surgery (Herrero-Vanrell et al., 2011b ).
According to their structure, microparticles receive the name of microcapsules for reservoir structures or microspheres for matrix systems (Yasukawa et al., 2004) .
Microcapsules are formed by a core containing the drug, which is surrounded by a layer of a polymer or a mixture of several polymers. In the microspheres, the active substance is dispersed in the polymeric network (figure 2).
Once administered, microparticles can disappear or remain in the site of administration after releasing the drug. In case of chronic posterior segment diseases biodegradable microspheres are preferred. Their use as injectable devices has become more popular over the last few decades. The main objectives of the development of biodegradable microspheres for intraocular drug delivery have been to obtain long-acting injectable drug depot formulations and specific drug targeting options.
Intraocular microparticles allow the release of the encapsulated drug, bypassing the blood-ocular barrier. The main advantage of these formulations is that they can release the drug over time with one single administration, having the same effect as multiple injections. Sustained release of active substances from microspheres reduces the need for frequent administrations and enhances patient compliance. This strategy has gained a lot of attention, especially in chronic diseases that require low concentrations of an active substance for a long period of time .
Microparticles are good candidates to be used in personalized medicine as different amounts of particles can be administered depending on patient needs. For intraocular purposes, they must be biocompatible, safe and stable, demonstrating predictable degradation kinetics. All these requierements can be achieved by the adjustement of the parameters involved in the manufacturing procedure. Furthermore, other factors such as chemical modifications of the particle surface can optimize the functionality of the system or help induce the desired response.
Over the last years, a large variety of bioactive compounds has been included in microspheres (i.e. antiproliferatives, anti-inflammatories, immunosuppressants, antibiotics and even biological therapeutic agents). For the treatment of vitreoretinal diseases, microspheres can be administered by intravitreal, periocular or suprachoroidal injection (Yasukawa et al., 2004; Herrero-Vanrell et al., 2001; Herrero-Vanrell et al., 2011a) .
Biodegradable polymers such as gelatin, albumin, polyorthoesters, polyanhydrides and polyesters are preferred for the elaboration of microspheres intended for intraocular drug delivery, as they disappear from the injection site after delivering the drug (HerreroVanrell et al., 2013) . Among them, the derivatives of poly (lactic) acid (PLA), poly (glycolic) acid (PGA) and their copolymers poly (lactic-co-glycolic) acid (PLGA) are the most employed. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved these biopolymers for clinical use. For ophthalmic purposes, and especially for the treatment of posterior segment diseases, these erodible polymers have been employed to prepare different devices such as implants, scleral plugs, pellets, discs, films, and rods (Yasukawa et al., 2004) . The degradation rate of D-or L-PLA, DL-PLA, and PGA is slower than PLGA, making it possible to select the most adequate polymer to prepare the particles. Previous experience with these polymers has shown that PLGA 50:50 (50% lactide and 50% glycolide) has short in-vivo half-life of degradation (Herrero-Vanrell et al., 2001 ) and degrades relatively fast to metabolic lactic and glycolic acid that are readily eliminated from the body after suffering metabolism to carbon dioxide and water mediated by Kreb's cycle (Zimmer and Kreuter, 2005) .
The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies is discussed in this article.
Technological aspects of microspheres for intraocular administration
2.1.
Manufacturing of microspheres
There are different methods to prepare microparticles (microcapsules and microspheres). They are based on different physico-chemical events: solvent extraction/evaporation from an emulsion, aggregation by pH adjustment or heat, coacervation (phase separation), interfacial polymerization, ionic gelation and spray drying, among others.
The most common technique for elaboration of microspheres destined to intraocular drug delivery is the solvent extraction/evaporation method from an emulsion (Freitas et al., 2005) . In this technique, the polymer is first dissolved in a volatile solvent in which the drug is incorporated (inner phase). Once formed, this discontinuous phase is carefully added into a non-miscible solvent also called external phase, including a stabilizer to ensure the formation and maintenance of spherical droplets of the inner phase in the emulsion (figure 3). Then, the elimination of the dispersed phase solvent is performed by extraction/evaporation at room temperature or under vacuum, and as a result, solid polymeric microspheres are formed. Finally, the mature microspheres are recovered by filtration or centrifugation and dried (lyophillization is preferred because the high stability of the final product). Depending on the properties of the active substance, the inner phase can form different physico-chemical systems (dissolution, suspension or emulsion). In the case of biotechnological products a more sophisticated methodology is required because of their poor stability of these products during manufacturing (i.e.
proteins often have large globular structure and exhibit secondary, tertiary and, in some cases, quaternary structure that is necessary for biological activity). For these macromolecules, water-in-oil-in-water emulsion method (W1/O/W2), in which the protein is first dissolved in the inner aqueous phase (W1), is commonly employed. Other technological approaches are currently under study for encapsulation of biotechnological products. Among them, the inclusion of stabilizers (Freitas et al., 2005) The ability of the microparticulate systems to deliver the drug in a controlled fashion is studied by means of in-vitro release experiments. Assays must simulate the in-vivo conditions. To do this, particles are suspended in an aqueous solvent (usually PBS, pH 7.4) in sink conditions. Then, the samples are placed in a shaker bath with constant agitation. At fixed time intervals, the supernatant is removed, measuring the drug concentration (Herrero-Vanrell et al., 2007) . The same volume of fresh medium is replaced to continue the release study. Drug release studies can also be assessed by dyalisis. This method is especially useful for the release study of poor soluble drugs (He et al., 2006) . Additives can be employed to modulate the release rate of the active substance from the particles. The use of additives in the microparticulate technology will be more detailed below.
Sterilization of microspheres
Microspheres destined to intraocular administration must comply with the sterility assurance requirements described in Pharmacopoieas. A final sterilization is preferred over preparation of microspheres under aseptic conditions. A sterility assurance level (SAL) of 10 -6 (statistical probability of finding 1 contaminated unit is 1 million) is generally acepted for pharmacopoeial sterilization procedures (Yaman, 2001 ).
Among the final available sterilization methods, ethylene oxide, gamma irradiation and autoclaving are the most employed. However, their use is limited due to instability of the materials (drug and/or polymer) or the production of toxic residues during the process. Some of the biopolymers commonly used to prepare microparticles for ophthalmic drug delivery, such as PLA and PLGA cannot undergo terminal sterilization by steam in a standard autoclave. In the case of thermally sensitive biomaterials, gamma irradiation is one of the preferred options because of its high capacity of penetration. The gamma irradiation dose required to assure sterilization of a pharmaceutical product is 25 kGy (Herrero-Vanrell et al., 2001) . However, it is well known that γ-radiation can induce structural changes in both the polymer (Sintzel et al., 1998) and in the encapsulated drug, especially if the active molecule is a protein (Montanari et al., 1998; Jain et al., 2011 ). It has been described that irradiation can induce non-desired events such as dose-dependent chain scission as well as molecular weight reduction of the polymer, affecting the behaviour of the final product (Nijsen et al., 2002) . Moreover, in the case of proteins, special care must be put on denaturation and degradation processes because they affect the integrity and bioactivity of the therapeutic agent (Jain et al., 2011 (Sintzel et al., 1998) . The use of antioxidants combined with the inclusion of the active agent in its solid form has been proposed as a succesful technological strategy to promote protein stability during sterilization (Mohanan et al., 2012; Checa-Casalengua et al., 2012) .
Technological strategies to optimize the drug release from microspheres
As therapy must be directed to personalized medicine, the characteristics of the formulation must cover the particular requirements of the patient. With this idea, several 
Hydrophilic additives in microspheres
Hydrophilic additives have been employed to increase the encapsulation efficiency.
Lysozime as a model protein was encapsulated in biodegradable microspheres and the effect of different additives (amphiphilic stabilizer, basic salt and lyoprotectant) was evaluated. The highest encapsulation efficiency was observed by using NaHCO3 (15-94%) although the in-vitro release characteristics were worsened. Cooperative effects in terms of encapsulation of lysozime were described with the use of rat serum albumin (RSA), sucrose and NaHCO3 as additives during the microencapsulation procedure (Srinivasan et al., 2005) .
Adjuvants such as polyethylene glycol (PEG 1000), pluronic F68 or gelatin increased the drug release rate from PLGA microspheres destined to intravitreal administration.
Addition of PEG 1000 (30%) or pluronic F68 (3%) accelerated the release of cyclosporine (CyS) from PLGA microspheres (Mw 15,000 g/mol; 75:25) prepared by a extraction/solvent evaporation method. In this study, pluronic F68 increased the release of CyS more significantly and maintained the structural integrity of particles after 2 months of the release experiment (He et al., 2006) . Martinez Sancho et al. (2004a) incorporated gelatin in the aqueous phase of the O/W emulsion during the preparation of acyclovir loaded PLGA microspheres to produce a higher drug release rate. The optimizacion of the formulation was performed applying a two-factor level experimental design. The analyzed variables were the amount of the drug included in the formulation and the gelatin added to the continuous phase of the emulsion. The best formulation according to the results was prepared with a drug:polymer ratio of 2:10 and adding gelatin to the aqueous phase (final concentration 0.08%). Microspheres released acyclovir at a constant rate for 63 days (1.73  0.08 µg acyclovir/day/mg microspheres).
Thanks to the addition of gelatin, the optimized formulation reduced by 40% the theoretical dosage of microspheres to be administered with respect to initial studies.
Lipophilic additives in microspheres
Oily compounds have been included as additives in the microspheres to modulate the drug release rate. If microparticles are prepared by the solvent extraction/evaporation emulsion technique, the lipophilic substance is added to the organic phase of the emulsion, remaining inside the particles after maduration. In the past decades, our research group has been evaluating the inclusion of oily additives not only to control drug release but also to improve the technological properties of microspheres. They are able to promote an increase of drug encapsulation efficiency, extend the release of the active substances and even protect a biological product from degradation (Herrero-Vanrell et al., 1998; Martinez-Sancho et al., 2003; Barcia et al., 2005; Checa-Casalengua et al., 2011; Checa-Casalengua et al., 2012) .
Additives with pharmacological properties
An additional advantage of using adjuvants is that some of them own pharmacological properties that make them interesting in the ophthalmic therapy. This is the case of retinoic acid ( 
Syringeability and injectability of microspheres
Syringeability and injectability are key-product performance parameters of intraocular dosage forms. The former refers to the ability of an injectable therapeutic to pass easily through a hypodermic needle or transfer from a vial prior to an injection, while the latter is related to the performance of the intraocular formulation during injection. Suprachoroidal administration of microspheres requires more sophisticated technology.
Patel et al. (2011), have evaluated the use of microneedles for suprachoriodal injection of nanoparticles (20-1000 nm) and microparticles (10 μm). These devices penetrate only a few hundred micrometers into the sclera (Patel et al., 2012) . Parameters such as microneedle length, pressure and particle size are critical parameters to render optimal delivery into the suprachoroidal space.
Determination of the amount of microspheres for injection
The amount of microspheres to inject for the treatment of vitreoretinal diseases depends on the therapeutic window of the drug, its intravitreal pharmacokinetic as well as on the drug payload in the particles and its release kinetic (Barcia et al., 2009 ).
Theoretically, the amount of microspheres (A) to be intravitreally administered can be calculated through the following pharmacokinetic equation:
Where Css is the steady state concentration of the drug in the vitreous that must be achieved and maintained for therapeutic efficacy. Cl is the drug clearance in the vitreous.
Cl is a product of Ke (drug elimination constant in the vitreous) and Vd (vitreous distribution volume). K0 is the theoretical zero-order drug release rate per mg of microspheres.
If microspheres are administered by another route different than the direct deposit of the formulation in the vitreous cavity, the amount of microspheres for injection can be calculated by using pharmacokinetic modelling. In this case, different ocular tissues (sclera, choroid, retinal pigment epithelium and vitreous) must be introduced in the equation, also taking into account the clearance of the active substance via choroidal circulation (Ranta and Urtti, 2006) .
Tolerance of microparticles for intraocular administration
Tolerance studies for microspheres can be performed in-vitro and in-vivo (both in animals and humans).
In-vitro tolerance studies
In ; Kompella et al., 2003; Amrite and Kompella, 2005; Ranta and Urtti, 2006; Barcia et al., 2009 . Suprachoroidal administration using microneedles has been also performed (Patel et al., 2011; , 1991) . The permanence of the aggregate is variable as the polymer takes different times to degrade. By histological studies, a mild localized foreign body reaction was described after the administration of ganciclovir-loaded microparticles in rabbits. In the same study, histopathologic analysis at 4 and 8 weeks post-injection showed mononuclear cells and multinucleated giant cells surrounding the particles, with no involvement of the retina or other ocular structures (Veloso et al., 1997) . The studies showed minimal focal disruption of the retinal architecture in eyes receiving both ganciclovir-loaded and blank microspheres. In general, the foreign body response is associated with the type of polymer and decreased with time. Particles remained at the implantation site and, according to some authors, twelve weeks after injection in rabbit eyes only pieces of microparticles could be recognized remaining at the injection site (Visscher et al., 1985; Moritera et al., 1992) .
Among the clinical signs, inflammation is the most frequently described after intravitreal injection of PLGA microparticles in rabbits. This reaction is similar to the one reported for sutures made of PLGA and after intramuscular injection of particles in rabbits (Visscher et al., 1985) . Inflammation signs were associated to early stages after injection and disappeared 2-4 weeks after administration. In any case, no retinal and choroidal damage were observed 35 days after administration (Giordano et al., 1995) .
Periocular administration
No inflammatory reaction in the retina nor surrounding tissues has been associated to PLGA microspheres after periocular injection. Mild conjunctival congestion is the most frequent clinical sign reported. Periocular route allows higher amounts of particles in the injection site than intraviteral administration without noticeable adverse signs. Periocular injection in pigs of 100 mg of blank microspheres (42.5 μm) or microspheres containing 25% or 50% of the kinase inhibitor PKC412 (67.7 μm) caused mild conjunctival reaction that was similar among the three groups. There were no discernible signs of inflammation or irritation. Ten days after injection the microspheres appeared as bulges beneath the conjunctiva (Saishin et al., 2003) . Similarly, administration of PLGA microspheres loaded with celecoxib did not produce signs of inflammation 60 days after administration.
Furthermore, no significant changes were observed in the thickness of retinal layers between untreated rats and animals receiving the celecoxib microparticles. Visual inspection of the site of action (periocular tissue) did not reveal the presence of inflammation, including redness and edema (Amrite et. al, 2006) . In case of rabbits, no adverse signs were observed after juxtaescleral injection of 5 mg of PLGA particles (blank and loaded with dexamethasone) suspended in BSS. Authors reported only conjunctival congestion at the administration site (24 h and 2 weeks post-injection for unloaded microspheres and 24 h and 1 week for dexamethasone-loaded microspheres) and concluded that PLGA microparticles are suitable for juxtascleral injection in rabbits with no adverse affects (Herrero-Vanrell et al., 2010a) .
In terms of intraocular tolerance, the nature of the polymer is critical. Furthermore, the biological response to a biomaterial depends on the physiological nature of the tissue. Rincon et al. (2005) evaluated the response to microparticles prepared from an elastin derivative poly (valine-proline-alanine-valine-guanine) (VPAVG) in different tissues. The authors reported no inflammatory response after subcutaneous injection of different amounts of particles (1.5 mg and 2.5 mg) in the hind-paw of the rat. Similar results regarding to the absence of inflammation were reported after intravitreal injection of 2.5 mg of poly (VPAVG) microparticles in which a few rabbits of the experimental group presented inflammation signs (2/11). However, at the end of the study (28 days after injection) 45% (5/11) of the animals showed tractional retinal detachment. This adverse effect was related to certain fibroblastic activity induced by the polymer. These results confirm the importance of testing tolerance in the specific ocular site.
Suprachoroidal administration
Nanoparticles (20 nm and 500 nm) and microparticles (1 μm and 10 μm) of fluospheres were administered into the space located between the sclera and choroids (Patel et al., 2012) . The fundus of the injected rabbit eyes appeared normal with no inflammation or abnormalities as compared with uninjected eyes. Although special concern is related to the risk of visual-impairment after intravitreous injection of microparticles, this preliminary investigation in humans has shown the opposite. The tendency of the microspheres to aggregate and condensate at the site of the injection leaving a free visual axis was reported after clinical evaluation in patients receiving the treatment. No inflammation signs were reported although it should be taken into account that, in this case, the anti-inflammatory substance could attenuate the inflammatory reaction. with the topical administration of prednisolone (1%) and ciprofloxacin (3%) eye drops during 4 weeks. The safety of both treatments was evaluated (intraocular pressure, biomicroscopy, and ophthalmoscopic findings) resulting in the same ocular tolerance for both pharmacological therapies after cataract surgery.
Movement of particles after injection
The movement of particles after intravitreal and periocular injection has been studied in different animal models and humans.
Intravitreal administration
PLGA microparticles are not expected to move as they have the tendency to aggregate several days after their intravitreal injection, which has been previously observed in animals and humans (Giordano et al., 1995; Herrero-Vanrell et al., 2001 ., Cardillo et al., 2006; Barcia et al.,2009 ) (figure 6). In the case of intravitreal injection, the influence of the presence and absence of the lens on the movement of microspheres has been described in rabbits. Intravitreous injected microparticles (7-10 micrometer size) were retained in the vitreous cavity in phakic eyes while some particles moved to the anterior chamber in aphakic eyes (Algvere and Bill 1979) .
Periocular administration
In the case of periocular injection, the size of particles affects their ocular distribution.
After subconjunctival injection in rats, fluorescent polystyrene particles in the nano-size (20 and 200 nm) and micro-range (2 μm) behaved differently depending on their size.
While particles higher than 200 nm were retained in the site of injection up to 60 days, lower sizes were able to move across the sclera and were rapidly cleared by the systemic and lymphatic circulation (Amrite and Kompella, 2005) .
Degradation of PLA and PLGA microspheres
PLGA is amorphous and, in general terms, its degradation rate is faster than the one observed for the more crystalline PLA polymer. For example, the 50:50 PLGA has shorter half-life than the 75:25 PLGA, and this one degrades faster than PLA (Li, 1999) .
The degradation of these polymers takes place by hydrolysis of its ester linkages in the presence of water (Giordano et al., 1995) . Among the polymers with the same composition, the lower molecular weight of the polymers and copolymers the faster the degradation rate (Herrero-Vanrell and Refojo, 2001). microspheres showed a faster in-vitro release (98% of the encapsulated drug) in only 2 days, while the 3,400 g/mol and 4,700 g/mol PLA particles took almost 7 days to release 85% and 70% of the 5-FU, respectively. It is interesting to note that the presence of the drug may affect degradation time of the particles (Visscher et al., 1985; Maulding et al., 1991) . The influence of the acidic or basic properties of the active substance encapsulated in the microparticles in the enhancement of the hydrolytic degradation of the polymers has been reported (Delgado et al., 1996; Li 1999) . Morphology change studies in microspheres have been performed during the in-vitro release assays. ChecaCasalengua et al. (2011) observed no changes in the morphology of GDNF loaded microspheres after 2 weeks of the release study. However, surface erosion of the particles appeared at 4 weeks. The erosion resulted more evident and particles began to aggregate after 6 weeks of in-vitro incubation, being completed after 8 weeks of the assay (figure 7).
In-vivo degradation of microspheres
Degradation of erodible microparticle systems after injection depends on their characteristics (i.e. size, structure, drug loading) as well as on the polymer properties.
The amount and the size (total surface area) of the microspheres also govern the degradation rate. Smaller size microparticles degrade faster than larger sizes (HerreroVanrell et al., 2001; Grizzi et al., 1995) . As mentioned previously, experience has demonstrated that the PLA and PLGA polymers suffer biodegradation. The rate of polymer biodegradation (in-vitro and in-vivo) depends on PLA:PGA ratio and molecular weight of the polymer (higher molecular weights degrade slower than low molecular weight polymers) (Miller et al., 1977) . Furthermore, surgery procedures have shown to accelerate microparticle clearance. As an example, Moritera et al. (1991) studied the influence of vitrectomy in rabbits. Clearance from the vitreous cavity was accelerated in animals that underwent vitrectomy. According to authors, particles gradually reduced their size faster in vitrectomized eyes. On the other hand, when Giordano et al. (1995) evaluated the biodegradation and clearance time of unloaded microspheres of a relatively low molecular weight polymer (inherent viscosity 0.2 dL/g) from the vitreous cavity in rabbits after gas vitrectomy, they found evidence of the microparticles up to 24 weeks postinjection.
Microspheres as therapeutical tools for the treatment of vitreoretinal diseases
Microspheres phosphorothioate oligonucleotides to prevent post-surgical fibrosis.
Proliferative Vitreoretinopathy (PVR)
Microparticles intended for the treatment of PVR have been loaded with different drugs with antiproliferative activity (Moritera et al. 1991; . 
Uveitis
The term "uveitis" is used to denote any intraocular inflammatory condition without reference to the underlying cause (Rodriguez et al., 1996) . Corticosteroids have proven efficient anti-inflammatory activity for the treatment of acute ocular inflammations such as uveitis. Intravitreal injections of steroids provide therapeutic drug levels (Gaudio, 2004) but only for short periods of time. Due to the short half-life of corticosteroids the maintenance of effective intravitreal concentrations in the target site is difficult to attain (Kwak and D´Amico, 1992) . 
Diabetic Rethinopathy (DR)
The evaluation of microparticulate carriers loaded with budesonide and celecoxib has been assayed for the treatment of diabetic retinopathy. Comparison between nano-(50 μg) and microparticles (75 μg), loaded with budesonide were performed after subconjunctival injection of particles in rats. In this study, microparticles (3.60  0.01 µm) delivered the active substance in a more sustained fashion than nanoparticles (345  2 nm) (Kompella et al., 2003) . According to authors the nanosystems were removed more rapidly from the subconjunctival site of administration than microparticles. Nanoparticles, microparticles and budesonide in solution (75 µg) were administered in rat eyes. Different tissue levels (retina, vitreous, lens and cornea) were compared at different times after administration. On day 7 and 14 drug levels in the eyes treated with microspheres resulted higher compared with the solution and nanoparticles. Sustained release of celecoxib from PLGA (85:15) microspheres (1.11  0.08 μm) was evaluated in a diabetic rat model (Amrite et al., 2006) . A posterior subconjunctival injection of 0.05 mL of celecoxib-microsphere suspension (14.93% ± 0.21%) was usuful to inhibit diabetesinduced elevations in PEG2, VEGF and blood-retinal barrier leakage.
Macular edema (ME)
Macular edema (ME) is frequently treated with corticosteroids. Among them, triamcinolone is the most used.
Intravitreal administration
As previously cited, one of the first evaluations of PLGA microspheres in humans has been performed in patients suffering diffusse macular edema (Cardillo et al., 2006) .
Eyes treated with triamcinolone-loaded microspheres and showed marked decrease of retinal thickness as well as improved visual acuity for 12 months.
Periocular administration
Microspheres loaded with betamethasone appear under phase II/III clinical trial for the treatment of diabetic macular edema (Yasukawa et al., 2011) . The microspheres are intended for sub-Tenon injection. (2000) have described guanosine-loaded PLGA (75,000-100,000 g/mol) microspheres developed for a drug release of 1 week after intravitreal injection of the particles.
Cytomegalovirus retinitis (CMV)
CMV retinitis occurs in immunodeficiency patients and its progression can result in blindness from retinal detachment associated with retinal necrosis (Jab et al., 1989; Henry et al., 1987) . Although intravitreal ganciclovir injections provide effective intraocular drug concentrations, frequent injections are required to maintain therapeutic drug levels.
With the objective to avoid frequent injections, Veloso et al. (1997) The formulation maintained mean vitreal concentrations of ganciclovir at approximately 0.8 μg/mL for 14 days, whereas direct injections maintained drug levels above 0.8 μg/mL for only 54 hours.
Choroidal Neovascularization (CNV)
PLGA microspheres loaded with a kinase inhibitor PKC412 were periocularly injected in a porcine model of laser induced choroidal neovascularisation (CNV) obtained by laser photocoagulation (Saishin et al., 2003) . After the rupture of Bruch's membrane in eight locations, 100 mg of microspheres were injected in the animals. Microspheres loaded with different amounts of PCK412 (25 or 50%) were compared to blank microspheres. After 10 days, the areas of CNV at Bruch's membrane rupture sites were noticeable lower for PCK412 microspheres. PCK412 levels in vitreous, retina and choroids were detected 20 days after periocular injection for the 50% PCK412 loaded microparticles.
9.8. Degenerative diseases affecting the optic nerve. Glaucoma.
Neuroprotection has been proposed as a therapeutic option for the treatment of In-vitro release rate of GDNF from PLGA microspheres (ng GDNF/mg microspheres) and SEM images of particles at different time points of the study. During the first 2 weeks of incubation, particles kept a smooth surface. After 4 weeks, the erosion of the surface of microparticles was evident, and 2 weeks later they started to aggregate.
After 8 weeks of the release assay, microparticles were completely aggregated. 
